Erratum to: Drugs Ther Perspect (2014) 30:231–240 DOI 10.1007/s40267-014-0129-1

Page 233, Table 1, ‘How should it be used in special populations?’ subsection, ‘Pts who are hypersensitive to any substance in the formulation’ row: The cell entry in column 2, which previously read:

“Use is contraindicated in pts with hypersensitivity to AMB, soya, azo colouring agent E129 or lactose (i.e. rare hereditary problems of lactose intolerance, Lapp lactase deficiency or glucose–galactone malabsorption)”.

Should read:

“Use is contraindicated in pts with hypersensitivity to AMB, soya, azo colouring agent E129 or lactose (i.e. rare hereditary problems of lactose intolerance, Lapp lactase deficiency or glucose–galactose malabsorption)”.

Page 236, Column 2, lines 19–20: The following sentence, which previously read:

“In subgroup analyses of patients in ARIES-1, -2 and -E stratified by baseline PAH severity, treatment with ambrisentan 5 or 10 mg/day was associated with benefits in patients with both less severe (i.e. WHO FC II/II) or more severe (i.e. WHO FC III/IV) disease”.

Should read:

“In subgroup analyses of patients in ARIES-1, -2 and -E stratified by baseline PAH severity, treatment with ambrisentan 5 or 10 mg/day was associated with benefits in patients with both less severe (i.e. WHO FC I/II) or more severe (i.e. WHO FC III/IV) disease”.

Page 237, Column 2, paragraph 3, lines 15–29: The following reference (#5 in the reference list) that was previously cited in the paragraph:

“Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60–72”.

Should be replaced by the following reference:

Lepist E, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS One. 2014;9(1):e87548.